Justine Grixti

Grixti played an instrumental role in pilot programs that allowed traditional Maltese credit institutions to interface with decentralized finance (DeFi) liquidity pools. This was a first in Southern Europe, reducing transaction costs for cross-border trade by an estimated 40% in test cohorts.

Away from the boardroom, Justine Grixti is known for her off-the-record mentorship of female founders in STEM. Rather than launching a branded non-profit, she reportedly created an anonymous grant fund for Maltese women pursuing master’s degrees in computational finance. This aligns with her philosophy: "Do the work. The credit is optional."

Dr. Grixti’s academic journey began at the University of Malta, where she earned a Bachelor of Science in Biology and Chemistry. She later pursued a Master of Science (Medicine & Surgery, by research) at the same institution's Department of Pathology. justine grixti

in 2019. Since then, she has transitioned from a post-doctoral researcher working on CRISPR technology to a senior role where she leads high-impact projects. Key Specializations:

During her postgraduate studies, Dr. Grixti gained international recognition: Grixti played an instrumental role in pilot programs

: Recognized in 2023 for her positive influence on both the local and international research community.

Every time you speak publicly, you give competitors data. Grixti’s quietness forces rivals to guess her next move, keeping her perpetually one step ahead. Rather than launching a branded non-profit, she reportedly

If you'd like, I can focus on a specific part of her career: Her early in Malta Her recent CRISPR and COVID projects A fictionalized account of a day in her lab

Justine Grixti's music is a fusion of pop, rock, and electronic elements, with a hint of Mediterranean flair. Her songs often feature catchy melodies, infectious beats, and heartfelt lyrics, which have resonated with fans from diverse cultural backgrounds.

, which focuses on unlocking solute carrier (SLC) transporters to identify new therapeutic drug targets. Scientific Publications